Cargando…

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections

BACKGROUND: Dexlansoprazole has been shown to be efficacious for the treatment of gastroesophageal reflux disease. However, there is a paucity of data about its efficacy for Helicobacter pylori eradication. The aim of this study was to evaluate the efficacy of dexlansoprazole for H. pylori eradicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuo, Chia-Jung, Chen, Chun-Wei, Le, Puo-Hsien, Hsu, Jun-Te, Lin, Cheng-Yu, Cheng, Hao-Tsai, Su, Ming-Yao, Lin, Chun-Jung, Chiu, Cheng-Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732863/ https://www.ncbi.nlm.nih.gov/pubmed/31523277 http://dx.doi.org/10.1177/1756284819870960

Ejemplares similares

Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains
por: Kuo, Chia-Jung, et al.
Publicado: (2020)

A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection
por: Wu, Deng-Chyang, et al.
Publicado: (2016)

Pancolitis associated with higher mortality risk of cytomegalovirus colitis in patients without inflammatory bowel disease
por: Le, Puo-Hsien, et al.
Publicado: (2018)

Clinical characteristics of cytomegalovirus colitis: a 15-year experience from a tertiary reference center
por: Le, Puo-Hsien, et al.
Publicado: (2017)

Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of Helicobacter pylori: A pilot randomized trial
por: Elkhodary, Noha Mahmoud, et al.
Publicado: (2020)

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019)

Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID-19 pandemic
por: Chiu, Cheng-Hsun, et al.
Publicado: (2021)

Statins’ Regulation of the Virulence Factors of Helicobacter pylori and the Production of ROS May Inhibit the Development of Gastric Cancer
por: Lin, Ting-Yu, et al.
Publicado: (2021)

Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
por: Chen, Chieh-Chang, et al.
Publicado: (2020)

Vedolizumab combined with surgical resection successfully treated perforating Crohn’s disease with peritoneal space to rectal and vaginal fistulas: a case report
por: Chung, Meng-Wu, et al.
Publicado: (2021)

Systemic lupus erythematosus complicated by Crohn’s disease with rectovaginal fistula
por: Yeh, Heng, et al.
Publicado: (2021)

The effect of prophylactic hemoclip placement and risk factors of delayed post-polypectomy bleeding in polyps sized 6 to 20 millimeters: a propensity score matching analysis
por: Chen, Chun-Wei, et al.
Publicado: (2020)

Campylobacter jejuni Cytolethal Distending Toxin C Exploits Lipid Rafts to Mitigate Helicobacter pylori-Induced Pathogenesis
por: Yeh, Jia-Yin, et al.
Publicado: (2021)

Dual Biologic Therapy for Refractory Crohn's Disease With Perforation in a Patient Declining Surgical Intervention
por: Le, Puo-Hsien, et al.
Publicado: (2023)

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Helicobacter pylori cholesterol-α-glucosyltransferase manipulates cholesterol for bacterial adherence to gastric epithelial cells
por: Hsu, Chung-Yao, et al.
Publicado: (2021)

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
por: Chiang, Hung-Hsien, et al.
Publicado: (2019)

Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
por: Yeh, Heng, et al.
Publicado: (2021)

Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory Clostridioides difficile infection and report of preliminary outcome
por: Yeh, Yuan-Ming, et al.
Publicado: (2022)

Inhibition of Helicobacter pylori CagA-Induced Pathogenesis by Methylantcinate B from Antrodia camphorata
por: Lin, Chun-Jung, et al.
Publicado: (2013)

Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori
por: YUAN, YUPING, et al.
Publicado: (2015)

Amikacin/dexlansoprazole: Laryngitis: case report
Publicado: (2021)

First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017)

Statins Attenuate Helicobacter pylori CagA Translocation and Reduce Incidence of Gastric Cancer: In Vitro and Population-Based Case-Control Studies
por: Lin, Chun-Jung, et al.
Publicado: (2016)

Helicobacter pylori and Systemic Disease
por: Kuo, Chao-Hung, et al.
Publicado: (2014)

Clinical manifestations, risk factors, and prognostic factors of cytomegalovirus enteritis
por: Yeh, Pai-Jui, et al.
Publicado: (2021)

The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2014)

Risk Factors, Clinical and Endoscopic Features, and Clinical Outcomes in Patients with Cytomegalovirus Esophagitis
por: Yeh, Pai-Jui, et al.
Publicado: (2022)

Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
por: Frye, Jeanetta W, et al.
Publicado: (2015)

Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
por: Tai, Wei-Chen, et al.
Publicado: (2013)

Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study
por: Chotivitayatarakorn, Peranart, et al.
Publicado: (2017)

Efficacy of Two Triple Eradication Regimens in Children with Helicobacter pylori Infection
por: Choi, Jungi, et al.
Publicado: (2006)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

Prognostic Significance of Perineural Invasion in Patients with Stage II/III Gastric Cancer Undergoing Radical Surgery
por: Chen, Yi-Fu, et al.
Publicado: (2022)

The Effect of Helicobacter pylori Eradication on the Levels of Essential Trace Elements
por: Wu, Meng-Chieh, et al.
Publicado: (2014)

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Effects of Multi-Strain Probiotics on Immune Responses and Metabolic Balance in Helicobacter pylori-Infected Mice
por: Lin, Chun-Che, et al.
Publicado: (2020)

Structures of Helicobacter pylori Shikimate Kinase Reveal a Selective Inhibitor-Induced-Fit Mechanism
por: Cheng, Wen-Chi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k6b9sq93nplfo7hqhj9jru54l2